US Stock MarketDetailed Quotes

WINT Windtree Therapeutics

Watchlist

3.4400
-0.0300-0.86%

Close Feb 27 16:00 ET

3.4900
+0.0500+1.45%

Post 20:01 ET

760.16KMarket Cap0.00P/E (TTM)

Windtree Therapeutics Stock Forum

Jaguar8

Feb 23 16:48

🟡Watchlist, FEBRUARY 24,2025, Monday. NFA - DrJag8 (Don’t ask stocks not in my list. It means it’s not in my radar).

NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press rele...

Benjamin Franklin 76

Feb 23 06:22

FORM S-1REGISTRATION STATEMENTUNDERTHE SECURITIES ACT OF 1933

$Windtree Therapeutics (WINT.US)$
gov/ix?doc=/Arc...⬅️⬅️⬅️⬅️

Grass Cow : Sorry to ask but what does it mean? I’m not very familiar to the form? Thanks

Report
Reply

Cancel Reply
Benjamin Franklin 76 OP Grass Cow : A **Form S-1 Registration Statement** under the **Securities Act of 1933** is a filing required by the U.S. Securities and Exchange Commission (SEC) for companies planning to issue new securities to the public, typically in an initial public offering (IPO) or other public offerings. It’s a foundational legal document designed to ensure transparency and protect investors by requiring companies to disclose critical information about their business, financials, and the securities being offered.
Here’s a breakdown of what it entails:
### Purpose
The Form S-1 is used to register securities with the SEC before they can be sold to the public. It provides investors with the information they need to make informed decisions, fulfilling the Securities Act’s mandate to promote transparency in the financial markets.
### Key Components
The Form S-1 typically includes:
1. **Prospectus**: The main section investors see, detailing:
- The company’s business model, operations, and industry.
- The purpose of the offering (e.g., raising capital for expansion).
- The number and type of securities being offered (e.g., common stock, preferred stock).
- Risk factors that could affect the investment.
- Use of proceeds (how the company plans to spend the money raised).
2. **Financial Statements**: Audited financials, including balance sheets, income statements, and cash flow statements, usually covering the past few years.
3. **Management Discussion and Analysis (MD&A)**: Insights from the company’s leadership about its financial condition and future outlook.
4. **Details About Management and Ownership**: Information on key executives, directors, and major shareholders.
5. **Legal and Regulatory Information**: Any ongoing litigation, regulatory issues, or material agreements that could impact the company.
6. **Underwriting Details**: Information about the investment banks or brokers helping sell the securities.
### Filing Process
- A company submits the Form S-1 to the SEC, where it’s reviewed for completeness and compliance.
- The SEC may provide comments, prompting revisions before approving the filing.
- Once approved (or “declared effective”), the company can proceed with selling the securities to the public.
### Who Uses It?
- **New Public Companies**: Most commonly, it’s filed by companies going public for the first time (IPOs).
- **Existing Public Companies**: Occasionally used by already-public companies issuing new securities, though they might qualify for simpler forms (like S-3) if they meet certain criteria.
### Importance
The Form S-1 is a critical tool for investor protection. By mandating detailed disclosures, it helps prevent fraud and ensures that companies can’t hide material risks or financial weaknesses. For example, if a company’s S-1 reveals heavy debt or a shaky revenue model, investors can weigh that before buying in.
It’s a dense, technical document, but it’s publicly available on the SEC’s EDGAR database once filed, so anyone can dig into the nitty-gritty of a company entering the public market.

Report
Reply

Cancel Reply
Benjamin Franklin 76 OP : Windtree Therapeutics recently filed a Form S-1 with the SEC on February 14, 2025. This filing is tied to their plan to register new securities, likely to raise capital, a common move for small-cap biotech firms like WINT that often need funding for research and development. The S-1 was filed just before a 1-for-50 reverse stock split, effective February 20, 2025, which reduced their outstanding shares to under 1 million, shrinking the float to around 700,000 shares. A reverse split is typically done to boost the stock price (in this case, from pennies to around $5) to meet NASDAQ listing requirements or make the stock more appealing to investors.
The Form S-1 likely details an offering of new shares, which could dilute existing shareholders . The filing would include the number of shares to be offered, the proposed price, financial statements, risks (e.g., their cash burn rate or clinical trial uncertainties), and how they intend to use the proceeds—probably to advance their pipeline, like their lead candidate istaroxime for heart failure.
Post-split, WINT closed at $4.35 on February 21, down from its reverse-split basis of $5, suggesting early selling or lack of buying momentum. X chatter indicates mixed sentiment: some see the low float as a chance for a bounce (like other squeezed low-float stocks), while others predict a quick drop below $1 if the offering floods the market. Windtree’s history of cash struggles and clinical-stage risks (no approved products yet) adds to the skepticism.
In short, WINT’s S-1 is a registration for a new securities offering, filed before a reverse split to shore up their share price and likely aimed at raising funds. It’s a standard move for a company in their position, but the timing and dilution risk have investors wary.

Report
Reply

Cancel Reply
Grass Cow Benjamin Franklin 76 OP : Thanks heaps for the detailed explanation. Appreciate it!

Report
Reply

Cancel Reply

rmgm

Feb 21 03:50

$Windtree Therapeutics (WINT.US)$ The 24 million additional new shares registered few days before the R/S has not been updated yet on the stock info here and other websites. check the market cap yesterday . divide that by the new 700 K post R/S float and you will be shocked .

In His GraceMercy

Feb 21 01:47

Potential Post R/S Squeeze? Let's see. Thoughts are welcome.

$Windtree Therapeutics (WINT.US)$
Theoretical Post-Split Price: $0.1263 × 50 = $6.315.
Post-Split Float: ~70,000 shares.
Post-Split Short Interest: ~3,900 shares (5.56% of float).
Days to Cover Post-Split: Pre-split volume (650,000 ÷ 50 = 13,000 shares/day),3,90013,000≈0.3\frac{3,900}{13,000} \approx 0.313,0003,900≈0.3days.
Analysis:
Low Short Interest: 5.56%
Tiny Float: 70,000 shares is ultra-low, making it hypersensitive to buying.
V...

Jaguar8

Feb 20 21:50

🟤Watchlist, FEBRUARY 21,2025, Friday. NFA -DrJag8

Hoᛋᛋ

Feb 19 08:17

$Windtree Therapeutics (WINT.US)$ This POS need delisted, the board needs public tar & feathering.

74547386

Feb 18 19:38

A Poem For My Fellow WINT Chasers

$Windtree Therapeutics (WINT.US)$
"From Regret, We Rise"
--- DS
Regret sits heavy, a stone in your chest,
A choice once made, now leaves you distressed.
The promise of gold, now ash in your hand,
A dream turned trap, not what you planned.

You mourn the loss, the trust betrayed,
The price of hope, so dearly paid.
Yet in this ache, let comfort be near,
For every fall brings wisdom clear.

The past is written...

rmgm

Feb 18 07:09

$Windtree Therapeutics (WINT.US)$ 50 to 1 Reverse Split , Adjusted price trading on 21 February . Total shares will be 700K so it is now 35 mil shares not 11 mil. They registered 24 mil new shares in the past few days .